Kymera slides after Q1 results as investors weigh cash burn and R&D ramp
KYMR•Kymera Therapeutics shares fell about 4% to $80.18 on Thursday, April 30, 2026, after the company reported Q1 2026 results and issued an updated business outlook. Despite a revenue and EPS beat, investors appeared to focus on ongoing cash burn and higher operating expenses tied to pipeline investment.
1. What’s moving the stock
Kymera Therapeutics (KYMR) is down roughly 4% Thursday after reporting first-quarter 2026 financial results and providing a business update. The move looks driven by investors rotating out despite headline beats, with attention on continued net losses and the cost ramp required to push multiple immunology degraders forward in the clinic. (investors.kymeratx.com)
